IN THIS ISSUE

Sarah Collins, MBA
Just because Medicare is hobbled in what it can do with comparative effectiveness research, doesn’t mean that MCOs cannot use the information for both quality improvement and cost control
Bob Kirsch
Atrial fibrillation patients are often noncompliant with warfarin but newer drugs have better safety and side effect profiles
Peer-Reviewed
Amy K. O'Sullivan, PhD
Jane Sullivan, MPH
Keiko Higuchi, MPH
Legislation & Regulation
John Carroll
In addition to the 85 percent rule, the department is applying a ‘reasonableness’ criterion. But it’s all bark, no bite.
Medication Management
Thomas Reinke
In an effort to make the best use of specialty drugs, everybody gets into the act at Independence Blue Cross
Plan Watch
Frank Diamond
BlueCross BlueShield of North Carolina’s vigorous patient-centered medical home may be an example to other plans and providers
Tomorrow's Medicine
Thomas Morrow, MD
NuView Life Sciences fuses molecular biology with imaging technology using the radioactive nuclide Copper 64
News and Commentary